Search Results for “cardiovascular” – Page 44 – media

EU OKs low-dose Xarelto to prevent recurrent VTE

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
- Source: Pharmatimes
- 622
- November 8, 2017
cardiovascular New Approvals venous thromboembolism VTE
Low vitamin D may raise risk of kidney failure

New research, conducted by scientists at the Johns Hopkins University School of Medicine in Baltimore, MD, finds that low vitamin D raises the risk of organ damage and renal disease in people with lupus – an autoimmune disease.
- Source: medicalnewstoday
- 1,060
- November 8, 2017
autoimmune inflammation lupus Researches SLE vitamin
Moderna Announces New Collaboration with AstraZeneca

Moderna Therapeutics today announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize a messenger RNA (mRNA) therapeutic encoding for Relaxin. The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
- Source: Modernatx
- 465
- November 7, 2017
heart Market Views mRNA
Just two sugary drinks per week may raise type 2 diabetes risk

The World Health Organization (WHO) report that at least 19 million yearly deaths are from cardiometabolic disorders – an umbrella term for cardiovascular disease and conditions such as metabolic syndrome and type 2 diabetes.
- Source: medicalnewstoday
- 590
- November 7, 2017
cardiometabolic diabetes Market Views WHO
The fight against obesity–To tax or not to tax?

The debate explores whether food taxation is an indispensable strategy to correct obesity trends, or whether there should be other ways of approaching the problem.
- Source: Medicalxpress
- 500
- November 6, 2017
food taxation obesity
China’s Import and Export Report of Antineoplastic Drugs

Antineoplastic or anticancer drugs, affect the process of cell division i.e. are antiproliferative. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells. Commonly used antineoplastic drugs can be divided into the following six categories: alkylating agents, anti-metabolites, anticancerous, antibiaties, aminoglutethimide and others. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, shares China’s Import and Export Report of Antineoplastic Drugs with you. General situation of global market of antineoplastic drugs According to the IMS’s latest report, “Global Oncology Trends 2017” showed that in 2016 the global market sales of antineoplastic drugs were 89.6 billion USD and 85 billion USD in 2015. Over the past five years, the global market of antineoplastic drugs has grown at a compound annual growth rate (CAGR) of 8.7% and is expected to exceed 147 billion USD by 2021. As indicated on the chart, the United States, the European Union and Japan are still the driving ...
- Source: Ddu
- 1,498
- November 3, 2017
anticancer Antineoplastic Market Reports neoplastic cells
Sanofi, Regeneron’s biologic shines again in asthma trial

Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
- Source: Pharmatimes
- 1,076
- November 3, 2017
asthma Clinical Trial dupilumab
Dicerna Could Pocket $201M in NASH R&D Deal With Boehringer Ingelheim

Dicerna Pharmaceuticals and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases. Dicerna can get up to $201 million in upfront and success-based development and commercialization milestones for an undisclosed target.
- Source: biospace
- 541
- November 3, 2017
chronic liver diseases Market Views RNAi
Bristol-Myers, J&J sink cash into a new $95M European biotech fund

A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
- Source: Endpts
- 616
- November 3, 2017
diagnostics funding Market Views medical device therapeutics
Wearable Devices–A New Look For The Modern Clinical Trial

Clinical development has historically been a laborious and expensive process that stretches across all therapeutic areas. It is driven by lengthy patient recruitment timelines, increasingly complex study designs, and high procedural costs. Depending on whose data you believe, getting a new drug to market can now cost upwards of $1 billion and take more than 10 years or research and development effort. Additionally, a complex and dynamic regulatory framework has made sponsors reluctant to introduce new technologies to facilitate the development process.
- Source: clinicalleader
- 987
- November 2, 2017
Artificial Intelligence Clinical machine learning Researches wearables

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.